Association pour la Recherche sur le Cancer - Espace dédié aux chercheurs

Accéder à mon espace

Déjà inscrit, identifiez-vous :

Interview of Zdenko Herceg

Zdenko Herceg is the Head of the Group “Epigenetics” and since 2011, of the Section “Mechanisms of Carcinogenesis” at the International Agency for Research on Cancer (IARC, also known as CIRC in French) located in Lyon. He joined IARC in 1997 after a Ph.D. from the University of St Andrews (UK) in the field of oncogenic transformation of human epithelial cells, and a post-doctorate in the Research Institute of Molecular Pathology (IMP) in Vienna, Austria.

                                                                                                         

His laboratory conducts both mechanistic studies and epigenetic profiling, aiming to gain a better mechanistic understanding of tumorigenesis, and to discover and validate new cancer biomarkers. His research exploits new concepts in cancer epigenetics and recent technological advances in genomics and is carried out in close collaboration with national and international groups.*

 

Zdenko Herceg's research has been supported in part by funding from la Fondation ARC through five different grants. As he explains: "when I got the first funding I was a young scientist developing my own group and a new activity. Later on, these contributions helped me to set up successful collaborations, to build up a research team and my own scientific career as the head of a group and later as head of research section". In this exclusive interview, Zdenko Herceg comments on his work on the role of epigenetics in cancer development.

 

 

*For more information of Zdenko Herceg’s work :http://www.iarc.fr/en/research-groups/EGE/staff.php

 

 

Entretien réalisé par A.G.

 

Crédits photos: Fondation ARC

 

Dernière mise à jour : 07/12/2012

Evènements / Agenda

27/11/2014

Cette journée permettra au Directeur scientifique du Cancéropôle IDF, Pierre Laurent-Puig, de présenter les orientations stratégiques et...

01/12/2014

La lutte contre les cancers s'inscrit dans une dynamique nationale et les enjeux de la cancérologie française restent nombreux : défis médicaux,...

04/12/2014

Immunothérapie et Chimiothérapie : Antagonisme ou Complémentarité ?

Haut de page